Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

NCT05523661 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Ph Positive ALL
CAR-T Cell
Dasatinib

Interventions

DRUG: Dasatinib plus anti-CD19/CD22 CAR-T cells

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine